S143 Serum CYFRA 21–1 as a prognostic marker in scleroderma-associated interstitial lung disease

Guilt by association: ILD genetics and co-morbidities Pub Date : 2018-12-01 DOI:10.1136/THORAX-2018-212555.149

C. Stock, R. Hoyles, C. Daccord, M. Kokosi, V. Alfieri, C. Campochiaro, J. Donovan, L. Mori, T. Maher, V. Kouranos, G. Margaritopoulos, P. George, P. Molyneaux, F. Chua, D. Abraham, V. Ong, C. Denton, A. Wells, E. Renzoni

{"title":"S143 Serum CYFRA 21–1 as a prognostic marker in scleroderma-associated interstitial lung disease","authors":"C. Stock, R. Hoyles, C. Daccord, M. Kokosi, V. Alfieri, C. Campochiaro, J. Donovan, L. Mori, T. Maher, V. Kouranos, G. Margaritopoulos, P. George, P. Molyneaux, F. Chua, D. Abraham, V. Ong, C. Denton, A. Wells, E. Renzoni","doi":"10.1136/THORAX-2018-212555.149","DOIUrl":null,"url":null,"abstract":"Interstitial lung disease (ILD) is the main cause of death in systemic sclerosis (SSc). The progression of SSc associated ILD (SSc-ILD) is highly variable. Markers predictive of progressive ILD are needed early in the disease course, to appropriately target patients at risk of developing progressive pulmonary fibrosis. CYFRA 21–1 (CYFRA) is a tumour marker expressed by type I/type II pneumocytes and respiratory bronchiolar epithelial cells, released into the blood following cell lysis. Serum levels of CYFRA were measured in both a retrospective (n=180) and a prospective (n=118) cohort of SSc patients. Retrospective cohort mean age: 49.1 (range 47.08–51.05), 77.25% female, prospective cohort age: 56.4 (54.10–58.73), 76.23% female. Median FVC% predicted and DLCO% predicted: retrospective cohort: 80.1% (IQR:67.2–95.5) and 55.5% (44.3–68.35), respectively – prospective cohort: 73.8% (57.2–87) and 39.9% (29.2–48.8), respectively. ILD was defined as the presence of fibrosis on chest imaging (chest x-ray or HRCT) and/or a forced vital capacity (FVC)","PeriodicalId":164956,"journal":{"name":"Guilt by association: ILD genetics and co-morbidities","volume":"123 5 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Guilt by association: ILD genetics and co-morbidities","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/THORAX-2018-212555.149","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Interstitial lung disease (ILD) is the main cause of death in systemic sclerosis (SSc). The progression of SSc associated ILD (SSc-ILD) is highly variable. Markers predictive of progressive ILD are needed early in the disease course, to appropriately target patients at risk of developing progressive pulmonary fibrosis. CYFRA 21–1 (CYFRA) is a tumour marker expressed by type I/type II pneumocytes and respiratory bronchiolar epithelial cells, released into the blood following cell lysis. Serum levels of CYFRA were measured in both a retrospective (n=180) and a prospective (n=118) cohort of SSc patients. Retrospective cohort mean age: 49.1 (range 47.08–51.05), 77.25% female, prospective cohort age: 56.4 (54.10–58.73), 76.23% female. Median FVC% predicted and DLCO% predicted: retrospective cohort: 80.1% (IQR:67.2–95.5) and 55.5% (44.3–68.35), respectively – prospective cohort: 73.8% (57.2–87) and 39.9% (29.2–48.8), respectively. ILD was defined as the presence of fibrosis on chest imaging (chest x-ray or HRCT) and/or a forced vital capacity (FVC)

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

血清CYFRA 21-1作为硬皮病相关间质性肺疾病的预后标志物

间质性肺疾病(ILD)是系统性硬化症(SSc)的主要死亡原因。SSc相关ILD (SSc-ILD)的进展是高度可变的。在病程早期需要预测进行性ILD的标志物，以适当地靶向有发展为进行性肺纤维化风险的患者。CYFRA 21-1 (CYFRA)是一种肿瘤标志物，由I/ II型肺细胞和呼吸细支气管上皮细胞表达，在细胞裂解后释放到血液中。在回顾性(n=180)和前瞻性(n=118) SSc患者队列中测量血清CYFRA水平。回顾性队列平均年龄:49.1岁(47.08-51.05)，女性77.25%;前瞻性队列平均年龄:56.4岁(54.10-58.73)，女性76.23%。预测FVC%和DLCO%的中位数:回顾性队列分别为80.1% (IQR: 67.2-95.5)和55.5%(44.3-68.35)，前瞻性队列分别为73.8%(57.2-87)和39.9%(29.2-48.8)。ILD定义为胸部影像学(胸部x线或HRCT)和/或用力肺活量(FVC)出现纤维化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助